{{Rsnum
|rsid=1846644
|Gene=KSR2
|Chromosome=12
|position=117500575
|Orientation=minus
|GMAF=0.3196
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=KSR2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 25.7 | 58.4 | 15.9
| HCB | 57.8 | 37.0 | 5.2
| JPT | 47.8 | 45.1 | 7.1
| YRI | 72.1 | 25.9 | 2.0
| ASW | 59.6 | 33.3 | 7.0
| CHB | 57.8 | 37.0 | 5.2
| CHD | 60.6 | 33.9 | 5.5
| GIH | 22.8 | 43.6 | 33.7
| LWK | 72.7 | 22.7 | 4.5
| MEX | 31.0 | 48.3 | 20.7
| MKK | 59.0 | 37.8 | 3.2
| TSI | 33.3 | 51.0 | 15.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1846644
|Name_s=
|Gene_s=KSR2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. In combination, rs10018204, rs11222869, rs16965867, rs1846644, and rs6539870 were significant predictors of etoposide IC50, accounting for 55% of the etoposide IC50 variation in Caucasians. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109342
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1846644
|overall_frequency_n=39
|overall_frequency_d=128
|overall_frequency=0.304688
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=28
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}